MDACC Study No:COGAALL0932 ( NCT No: NCT01190930)
Title:AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Principal Investigator:Cesar Nunez
Treatment Agent:6-mercaptopurine; Cyclophosphamide; Cytarabine; Dexamethasone; Methotrexate; Pegasparagase; Vincristine
Study Status:Open
Study Description:The goal of this part of the clinical research study is to collect information
about the quality of life of children with AR B-ALL.

This study is called a clinical trial. A clinical trial is a research study
involving treatment of a disease in human patients. This study is organized by
Children's Oncology Group (COG). COG is an international research group that
conducts clinical trials for children with cancer. More than 200 hospitals in
North America, New Zealand and Europe are members of COG.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Pediatrics
Phase of Study:Phase III
Treatment Agents:6-mercaptopurine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:The Children's Oncology Group (COG)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Cesar Nunez
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults